8 results about "Erythrocyte binding" patented technology

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

The present disclosure relates to synthetic Plasmodium reticulocyte binding protein 2b (mRBP2b) antigens that have improved properties such as thermal stability, as well as the use of these antigens to detect a Plasmodium infection in a diagnostic device or for use in a vaccine.

A polypeptide specifically binding to an erythrocyte membrane or a mutant thereof. The polypeptide or mutant thereof can be fused with various recombinant proteins. By using the binding property of the polypeptide or mutant thereof to erythrocytes and dynamically balancing the binding to and releasing from an erythrocyte membrane, the sustained release of a drug can be achieved, thereby prolonging the circulation half-life of the drug.

The invention provides application of red blood cells as an M protein carrier in diagnosis of monoclonal immunoglobulin diseases, and proves that the monoclonal immunoglobulin combined with the red blood cells exists in peripheral blood for the first time, and not only the complete monoclonal immunoglobulin but also a monoclonal light chain or a monoclonal heavy chain exists. Polyclonal immune globulin in normal serum is rarely combined with erythrocytes, so that electrophoresis by using erythrocyte protein is more sensitive and recognizable than electrophoresis by using plasma to identify M protein and isotype thereof. The invention provides the application of the reagent for detecting the erythrocyte M protein in diagnosis or auxiliary diagnosis of the monoclonal immunoglobulin disease, and a favorable tool is provided for positioning the M protein isotype disease of a patient and guiding the monoclonal guide treatment.

Biomarkers, such as erythrocyte-bound C4d. B-lymphocyte-bound C4d. anti-nuclear antibody. Sjögren's syndrome type B antigen, Scl-70 antibody. Jo-1 antibody, and anti-centromere protein B. can be used to diagnose. prognose, monitor, and treat subjects having systemic lupus erythematosus.

Methods are provided for modulation of FcgR expression on myeloid cells during administration of anti-CD47 antibodies to achieve improved therapies. In some embodiments, it includes compositions and methods d relating to antibodies that bind to CD47 and block the interaction between CD47 and SIRPa. Administration of an anti-CD47 antibody in vivo can result in binding of the antibody to red blood cells (RBC). The antibody-antigen complex formed by this binding is "pruned" from the RBC surface, resulting in a dramatic loss of erythrold surface CD47.

Methods of detecting biomarkers in a blood sample obtained from a human subject include detecting an erythrocyte-bound C4d (EC4d) marker, a B-lymphocyte-bound C4d (BC4d) marker, and an anti-nuclear antibody (ANA) in the blood sample; and detecting a level of double-stranded DNA antibody in the blood sample, wherein the human subject is negative for systemic lupus erythematosus based on the level of double-stranded DNA antibody. The methods optionally further include determining a systemic lupus erythematosus risk score by: (a) adjusting the level of EC4d marker by a weighting coefficient to produce a weighted score for EC4d marker; (b) adjusting the level of BC4d marker by a weighting coefficient to produce a weighted score for BC4d marker; (c) adjusting the level of ANA by a weighting coefficient to produce a weighted score for ANA; and (d) combining the weighted score for EC4d marker, the weighted score for BC4d marker, and the weighted score for ANA to generate the systemic lupus erythematosus risk score; wherein the systemic lupus erythematosus risk score does not include a score for double-stranded DNA antibody.

To solve the problems that sepsis is a disease with a high mortality rate, that since sepsis caused by gram-negative bacteria has a particularly poor prognosis, early diagnosis and appropriate treatment are necessary, and although detection of endotoxin is an important method for quickly diagnosing sepsis, there are still challenges in detecting endotoxin in blood.SOLUTION: In the present invention, erythrocytes, which have not received much attention in a blood sample until now, are used as a target for measuring endotoxin, thereby establishing a method for measuring total endotoxin in blood, which contributes to diagnosis of gram-negative bacterial sepsis.SELECTED DRAWING: Figure 1